APPLICATIONS

Effect of Flow Rate on Reversed Phase Separations of Monoclonal Antibodies

Cody Warhurst, Dawn Chen, Brian Rivera Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501

The analysis of intact monoclonal antibodies (mAbs) by reversed phase HPLC is a common technique for assessing protein variation, such as clipping and heterogeneity due to post-translational modifications. Whether for LC-UV impurity analysis or for confirming primary sequence using LC-MS, the analysis of intact mAbs can provide useful insight on a protein therapeutic.

Because of their slow diffusion rates, peak broadening is commonly observed with reversed phase analysis of proteins and other large molecules. This is also exacerbated by fundamental denaturing conditions of reversed phase LC, which can cause conformational changes to the protein, leading to further peak distortion.

However, analysis using superficially porous (core-shell) particles can minimize the diffusion distance, thus the amount of peak dispersion, that is inherent with large molecule LC analysis. Further, the significantly lower surface area of wide pore core-shell particles lends to an overall less hydrophobic phase and consequently lower organic solvent for elution. Utilizing a <u>bioZen™ 2.6 µm</u> <u>WidePore C4</u> LC column helps to improve peak shape by reducing band broading and enhancing efficiency but other adjustments can be made to further improvements.

As such, core-shell particles allow for expanding experimental design to include flow-rate, which can have a significant impact on the separation, both selectivity and peak capacity. Here, we investigate the impact of increasing flow-rate for NIST mAb, a common protein standard for evaluation and benchmarking analytical methods for protein characterization.

In assessing chromatographic performance, peak width at half height was used as the target attribute. **Figure 1** shows a comparison of intact NIST mAb, run at varying flow-rates, from 0.5 mL to 0.8 mL. There was a marked improvement in peak widths running at 0.8 mL/min; interestingly though 0.6 mL/min performed slightly worse than 0.5 mL/min, as there is a drop in resolution between the pre-peak and main peak (**Figure 2**). The effect of flow-rate changes is even more impactful for subunit analysis of mAbs. **Figure 3** shows a series of stacked chromatograms for reduced NIST mAb. Overall, there is a reduction in peak widths for both heavy chain and light chain with an increase in flow-rate. However, with heavy chain, we can observe not only a decrease in peak width at half height, but also an improvement in impurity profile, as another shoulder is observed at 0.8 mL/min when compared to 0.5 mL/min (**Figure 4**).

phenomene

In summary, increases in flow-rate with core-shell particles, such as the <u>bioZen WidePore C4</u>, can overcome the slow diffusion rates inherent with large molecules. In general, increases in flow-rate should reduce peak widths, thus improving overall chromatographic performance. This can be most impactful with subunit analysis of monoclonal antibodies. However, as observed with intact NIST mAb at 0.6 mL/min, one should experimentally determine the chromatographic impact of running higher flowrates, as unexpected results may occur.

LC Conditions

| Column: | bioZen 2.6 μm WidePore C4 |
|-------------------|--|
| Catalog No.: | 00D-4786-AN |
| Dimensions: | 100 x 2.1 mm |
| Mobile Phase A : | 0.1 % TFA in Water |
| Mobile Phase B: | 0.1 % TFA in Acetonitrile |
| Gradient: | 25-45% B in 6 minutes |
| Flow Rate: | As indicated |
| Temperature: | 90°C |
| Detection: | UV-Vis @ 280 nm (Fig 1,2) UV-Vis @ 214 nm (Fig 3,4) |
| Sample: | NIST mAb (1 mg/mL) |
| Injection Volume: | 2 μL |



Figure 1:

Stacked chromatograms of intact NIST mAb. An improvement in peak width at half height is observed at 0.8 mL/min when compared to 0.5 mL/min (0.030 vs 0.033, respectively)




Figure 3:

Light Chain and Heavy Chain for NIST mAb. Peak widths at half height improved for the earlier eluting light chain with increasing linear velocity; with peak widths improving when flow-rate is increased to 0.8 mL/min compared to 0.5 mL/min (0.025 vs 0.029, respectively).




Figure 2:

Overlay of intact NIST mAb; note the loss of resolution with 0.6 mL/min. when compared to 0.5 mL/min. This may be due to linear velocity not being scaled with change in organic solvent per column volume.





Figure 4:

Heavy Chain Overlay comparing 0.5 mL/min and 0.8 mL/min. Note the improvement in impurity profile with 0.8 mL/min, showing a shouldering of another late eluting variant.



Having trouble reproducing this method? We would love to help!

Visit www.phenomenex.com/LiveChat to get in touch with one of our Technical Specialists



APPLICATIONS

Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on <u>www.phenomenex.com</u>, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal <u>www.phenomenex.com/LiveChat</u>.

Australia t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

China t: +86 400-606-8099 cninfo@phenomenex.com

Denmark t: +45 4824 8048 nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

www.phenomenex.com

India t: +91 (0)40-3012 2400 indiainfo@phenomenex.com

Ireland t: +353 (0)1 247 5405 eireinfo@phenomenex.com

Italy t: +39 051 6327511 italiainfo@phenomenex.com

Luxembourg t: +31 (0)30-2418700 nlinfo@phenomenex.com

Mexico t: 01-800-844-5226 tecnicomx@phenomenex.com

The Netherlands t: +31 (0)30-2418700 nlinfo@phenomenex.com

New Zealand t: +64 (0)9-4780951 nzinfo@phenomenex.com

Norway t: +47 810 02 005 nordicinfo@phenomenex.com

Portugal t: +351 221 450 488 ptinfo@phenomenex.com Singapore t: +65 800-852-3944 sginfo@phenomenex.com

Spain t: +34 91-413-8613 espinfo@phenomenex.com

Sweden t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

United Kingdom t: +44 (0)1625-501367 ukinfo@phenomenex.com

USA t: +1 (310) 212-0555 info@phenomenex.com

All other countries Corporate Office USA t: +1 (310) 212-0555 info@phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com

BE-HAPPY[™] guarantee

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right. www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

bioZen is a trademark of Phenomenex.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2020 Phenomenex, Inc. All rights reserved.